In light of the important role of TAMs in conferring tumor progression, e.g., by neoangiogenesis, and in the release of anti-inflammatory mediators, such as IL-10, to promote tumor immune evasion [45], it is possible that inhibition of Fscn1 in TAMs may contribute to inhibition of tumor growth. The gene discussed is FSCN1; the disease is neoplasm.